A Randomized Intervention of Montelukast for Post-Bronchiolitis: Effect on Eosinophil Degranulation - 07/03/14
Reprint requests: Dr Young Yull Koh, Department of Pediatrics, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea.Abstract |
Objective |
To investigate the effect of montelukast on eosinophil degranulation and recurrent wheezing episodes in post-respiratory syncytial virus (RSV) bronchiolitis.
Study design |
Two hundred infants (age, 6-24 months) who were hospitalized with their first episode of acute RSV bronchiolitis were randomized in a double-blind, placebo-controlled, parallel comparison of 4-mg montelukast granules (RSV-MONT group) or matching placebo (RSV-PLC group) administered for 3 months. Serum eosinophil-derived neurotoxin (EDN) levels were measured (primary outcome), and recurrent wheezing was documented (secondary outcome) for 12 months. Comparisons were made with control subjects (control group, n = 50).
Results |
At the end of the 3-month treatment period, the RSV-PLC group (n = 71) exhibited significantly elevated EDN levels (P < .0001), and the RSV-MONT group (n = 79) showed significantly decreased EDN levels (P < .01) when compared with the initial levels. As a result, EDN levels in the 2 RSV groups significantly differed at this point (P < .0001) and remained different for the entire 12-month follow-up period. Cumulative recurrent wheezing episodes at 12 months were significantly lower in the RSV-MONT group (P = .039).
Conclusion |
Montelukast treatment reduces eosinophil degranulation and is associated with a decrease in recurrent wheezing episodes in post-RSV bronchiolitis.
Le texte complet de cet article est disponible en PDF.Mots-clés : CysLT, ECP, EDN, EPX, IL, LTRA, MONT, PLC, RSV
Plan
| Supported in part by a Korean Research Foundation grant to C-K.K. funded by the Korean Government (MOEHRD; KRF-2005-042-E00078) and in part by a research grant from the Investigator-Initiated Studies Program of Merck. Merck & Co., provided the inactive, oral, look-alike granules identical to 4-mg montelukast granules. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck. The authors declare no conflicts of interest. |
Vol 156 - N° 5
P. 749-754 - mai 2010 Retour au numéro
Article précédent
- Small Volumes of Feed Can Trigger Transient Lower Esophageal Sphincter Relaxation and Gastroesophageal Reflux in the Right Lateral Position in Infants
- Michiel P. van Wijk, Marc A. Benninga, Geoffrey P. Davidson, Ross Haslam, Taher I. Omari
- Risk Factors for Short- and Long-Term Morbidity in Children with Esophageal Atresia
- Julie Castilloux, Angela J. Noble, Christophe Faure
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?